Bioeasy Biotechnology, A101, Building 2, Bioeasy Industry Park, No. 289 Yunchang Road, Bao'an District, Shenzhen City, Shenzhen (2026)

12/02/2025

Leading the Charge in Food Safety: Bioeasy’s Milestone Achievement! 🚀

We are excited to share that Bioeasy is the first company in China to apply for both RMP (Standard Material Producer) and PTP (Proficiency Testing Provider) qualifications simultaneously, successfully passing the initial on-site evaluation by the China National Accreditation Service for Conformity Assessment (CNAS). 🎉
This achievement marks a key milestone in our journey to lead the food safety industry. With rising consumer demands for safer and healthier food, it’s critical to have trusted organizations offering standard material testing and proficiency validation to guarantee the highest quality.💯
At Bioeasy, we’re committed to innovation and excellence in food safety testing, and we’re ready to bring even more advanced solutions to the market. ✅

05/09/2024

Elevate Your Laboratory's Efficiency: Comparing Rayto LumiRay 630 and Mini VIDAS
In today’s fast-paced healthcare environment, laboratories are increasingly challenged to deliver rapid and accurate results while managing costs. Two prominent players in the immunoassay market, Rayto’s LumiRay 630 and BIOMERIEUX’s Mini VIDAS, offer unique features tailored to different laboratory needs. Understanding their differences can help you choose the right solution for your facility.

Throughput and Workflow Efficiency
One of the standout features of the LumiRay 630 is its impressive throughput of 80 tests per hour, making it ideal for medium to small-scale labs that require consistent and reliable results. This throughput strikes a balance between high performance and operational efficiency, allowing laboratories to handle moderate testing volumes without sacrificing quality.

In contrast, the Mini VIDAS is designed for lower-volume testing, primarily suited for urgent or single-sample tests. While it excels in delivering quick results for specific assays, it may not meet the needs of labs looking for continuous testing capabilities to support a steady workflow.

Automation and Ease of Use
The LumiRay 630 boasts several automated features, including automatic cuvette loading and a cap-piercing function, streamlining the testing process and reducing manual handling. This automation not only enhances operational efficiency but also minimizes the risk of errors, ensuring that labs can focus on delivering high-quality patient care.

The Mini VIDAS, while user-friendly, requires more manual intervention, which can slow down workflows and increase the potential for human error. Laboratories seeking to optimize their operations will find the automation of the LumiRay 630 to be a significant advantage.

Cost-Effectiveness
In a landscape where budgets are increasingly scrutinized, the LumiRay 630 stands out as a cost-effective alternative to high-end systems. By offering high throughput and automated processes at a competitive price point, it allows laboratories to expand their testing capacity without incurring significant investments.

On the other hand, while the Mini VIDAS provides valuable capabilities, its per-test costs can add up, especially for laboratories that need to perform a high volume of tests. This can lead to challenges in managing overall operational costs.

Versatility in Testing
The LumiRay 630 supports a wide range of assays, including whole blood tests for cardiac and inflammation markers, making it suitable for diverse laboratory needs. This versatility ensures that labs can respond to various testing demands without needing multiple systems.

In comparison, the Mini VIDAS focuses on specific assays, which, while effective, may limit its applicability for labs that require a broader testing scope.

Conclusion
Choosing between the Rayto LumiRay 630 and the Mini VIDAS ultimately depends on your laboratory’s specific needs. If you’re looking for a solution that offers high throughput, automation, cost-effectiveness, and versatility, the LumiRay 630 is the clear choice. It empowers labs to enhance their efficiency and deliver timely, accurate results, positioning them for success in a competitive healthcare landscape.

As the demands for laboratory testing continue to grow, selecting the right immunoassay system will be crucial in meeting both operational and patient care goals. The Rayto LumiRay 630 is here to help your lab rise to the occasion.

19/08/2024

Down Syndrome (Trisomy 21), its Cause and Risks
Also known as Trisomy 21, Down Syndrome is the most common chromosomal anomaly in humans. It is a genetic condition caused by an extra chromosome.

Most babies inherit 23 chromosomes from each parent, for a total of 46 chromosomes. Babies with Down syndrome however, end up with three chromosomes at position 21, instead of the usual pair.

As every child with Down syndrome grows, he is at greater risk for certain medical problems and may develop:
Congenital heart disease
Gastrointestinal abnormalities
Musculoskeletal and movement problems
Spine disorders such as scoliosis, kyphosis or lordosis
Endocrinologic disorders
Epilepsy
Hearing loss
Speech apraxia (difficulty making speech sounds)
Sleep disorders
Feeding disorders
Developmental disabilities (learning disabilities, intellectual disabilities and autism)

Treatments
There is no cure for Down syndrome (Trisomy 21).

This is the key reason why it is so important to screen Down syndrome (Trisomy 21) in Women’s first and second trimester of the pregnancy.

Maternal Serum Markers about Down Syndrome (Trisomy 21)
The tests of maternal serum markers can predict the risk of trisomy 21. Such markers include
1) Alpha-fetoprotein (AFP)
2) Unconjugated estriol (uE3)
3) Free Beta-Human Chorionic Gonadotropin (Free-β-HCG)
4) Pregnancy-Associated Plasma Protein A PAPP-A

AFP:
AFP is produced by the fetal yolk sac and fetal liver. Fetal plasma concentration increases to a maximum (approximately 3.0-4.0 g/L) between 13-14 weeks of gestation. Maternal serum levels peak at about 30 weeks (about 250 mg/L). After birth, maternal and infant AFP rapidly decline. The maternal serum AFP in the first and second trimester from pregnancies affected with fetal trisomy 21 was lower than compared to normal pregnancies. It was also demonstrated that the decrease in AFP was independent of maternal age, making prenatal screening for fetal Down’s syndrome possible in women less than 35 years old.

This association of decreased levels of AFP with an increased risk of Down syndrome led to the introduction of risk screening in which a woman's AFP level and age were used to estimate her odds of having an affected child. The levels of AFP in Down's syndrome pregnancies are about 72% of the normal values for weeks 15-20.

uE3:
Unconjugated estriol (uE3) shows a correlation between low uE3 and trisomy 21, with a high level of correlation between AFP and uE3. Estriol is produced by the placenta from maternal substrates (cholesterol and pregnenolone). Estriol diffuses from the placenta into the maternal blood where it can be measured as unconjugated uE3. In normal pregnancies uE3 levels increase from about 4ng/mL at 15 weeks gestation.

The first and second trimester maternal serum uE3 levels in Down's syndrome pregnancies are approximately 75% of the values expected in normal pregnancies.

Free-β-HCG:
Although the production of each subunit’s HCG messenger RNA is increased in Down syndrome pregnancies, beta subunit production is more markedly increased. This finding suggests that, the Free-β-HCG subunit might be superior to intact HCG for Down syndrome detection. Free-β-HCG subunit concentrations average 0.5% of total HCG levels.

Pregnancy-Associated Plasma Protein A (PAPP-A):
In the first-trimester, Free-β-HCG and PAPP-A screening for Down syndrome can achieve detection rates as high as those associated with AFP and HCG or AFP, HCG and uE3 in the second trimester.

Combined First and Second Trimester Screening Test
The first trimester screening is performed between 10 and 14 weeks of gestation. The major markers used for the risk calculation are 2 serum markers: PAPP-A and free β-HCG. Decreased levels of PAPP-A before the 14th week of gestation are associated with an increased risk for Down syndrome. Whereas increased levels of free β-HCG are associated with an increased risk of Down syndrome.

The second trimester screening is performed between 15 and 20 weeks of gestation. The markers used for the risk calculation are all 4 serum markers: AFP, uE3, PAPP-A and free β-HCG. Decreased levels of AFP and uE3 are associated with an increased risk for Down syndrome.

Rayto’s Chemiluminescent Solution to Down Syndrome Screening
Rayto is supplying whole sets of reagent kits (including calibrators and controls) to test AFP, uE3, free β-HCG and PAPP-A. Such kits are compatible for all types of Rayto’s LUMIRAY series analyzers. Please kindly contact us for more information, if interested.

28/06/2024

Unlocking the Future: Insights into the In Vitro Diagnostics (IVD) Industry
The In Vitro Diagnostics (IVD) industry is reshaping healthcare with innovative solutions that empower medical professionals to make informed decisions. Let's delve into the current trends, challenges, and opportunities in this dynamic field.

Market Momentum 🚀
The global IVD market is on a robust growth trajectory, driven by factors such as an aging population, rising prevalence of chronic diseases, and rapid technological advancements. According to Grand View Research, the market was valued at $68.41 billion in 2021 and is projected to grow at a CAGR of 4.5% from 2022 to 2030.

Key Segments 📊
Clinical Chemistry: Blood glucose, cholesterol, and electrolyte analysis form the backbone of routine diagnostics.
Molecular Diagnostics: PCR and next-generation sequencing are game-changers in detecting genetic disorders and infectious diseases.
Hematology: Complete blood counts (CBC) and coagulation tests are essential for diagnosing blood-related conditions.
Immunoassays: Vital for infectious disease testing, hormone assays, and cancer markers.
Microbiology: Essential for identifying and analyzing pathogens.
Tech Innovations 🌐
Point-of-Care Testing (POCT): Bringing rapid, on-site diagnostic capabilities closer to patients.
Automated Instruments: Enhancing efficiency and reducing errors with advanced automation.
Digital Pathology: Revolutionizing tissue analysis with high-resolution digital imaging.
Wearable Diagnostics: Offering continuous health monitoring for proactive disease management.
Regulatory Landscape 📋
Navigating the IVD industry requires stringent adherence to regulations set by bodies like the FDA, EMA, and ISO. These regulations ensure the safety and efficacy of diagnostic tests, a crucial aspect of maintaining market credibility.

Challenges & Opportunities ⚖️
Regulatory Hurdles: Keeping up with evolving regulatory requirements can be challenging.
Reimbursement Issues: Securing favorable reimbursement rates remains critical.
Tech Integration: Merging new tech with existing systems requires significant investment.
Opportunities:

Emerging Markets: Expanding healthcare infrastructure in emerging economies offers significant growth potential.
Personalized Medicine: Advances in genomics support the shift towards individualized treatment plans.
Collaborations: Partnerships drive innovation and market expansion.
The Road Ahead 🌟
The IVD industry stands at the forefront of healthcare innovation. With continuous technological advancements and a focus on personalized medicine, the future promises improved diagnostic capabilities and better patient outcomes.

Let's stay connected and explore how these trends will shape the future of healthcare. Your thoughts? Share in the comments below! 💬

17/06/2024

ADLM is one of the most important medical exhibitions in America. lt serves as an excellent platform for professionals, experts, and organizations in clinical laboratory science and its application to health care providing a comprehensive overview of the latest developments in laboratory medicine.
Rayto cordially invites business partners and distinguished guests to join the event at our booth 3356, to see what's new we get.

06/05/2024

First day back to work after a 5-day vacation, be like:

15/04/2024

Tumors and Cancer: Understanding the Difference

What is a Tumor?

A tumor is an abnormal growth of tissue that can form in any part of the body. Tumors can be caused by a variety of factors, including genetics, exposure to carcinogens, and inflammation.

Types of Tumors

There are two main types of tumors: benign and malignant.

Benign tumors are noncancerous and do not spread to other parts of the body. They are usually slow-growing and do not cause any symptoms. However, in some cases, benign tumors can grow large enough to press on nearby organs or tissues, causing pain or other problems.

Malignant tumors are cancerous and can spread to other parts of the body. They are often fast-growing and can cause a variety of symptoms, depending on the location and size of the tumor.

What is Cancer?

Cancer is a disease that occurs when cells in the body grow uncontrollably and invade and destroy healthy tissue. Cancer cells can also spread to other parts of the body through the bloodstream or lymphatic system.

Types of Cancer

There are many different types of cancer, which are classified by the type of cell that the cancer originates from. Some of the most common types of cancer include:

Skin cancer
Breast cancer
Lung cancer
Colon cancer
Prostate cancer
Symptoms of Cancer

The symptoms of cancer can vary depending on the type of cancer and the location of the tumor. However, some common symptoms of cancer include:

Unexplained weight loss
Fatigue
Fever
Pain
Changes in bowel or bladder habits
Unusual bleeding or discharge
Lumps or growths
Diagnosis and Treatment of Cancer

The diagnosis of cancer usually involves a combination of tests, such as physical examination, imaging tests, and biopsies. Treatment for cancer depends on the type of cancer, the stage of the cancer, and the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, and targeted therapy.

Prevention of Cancer

There are a number of things that people can do to reduce their risk of developing cancer, including:

Not smoking
Maintaining a healthy weight
Eating a healthy diet
Exercising regularly
Limiting alcohol consumption
Getting regular sun protection
Getting vaccinated against certain viruses, such as hepatitis B and human papillomavirus (HPV)
Tumor Marker Screening

Blood tests for tumor markers are a common way to screen for cancer. Tumor markers are substances that are released into the bloodstream by cancer cells. While tumor marker tests can be helpful in detecting cancer early, they are not always reliable and should be used in conjunction with other screening methods.

Conclusion

Tumors and cancer are serious conditions, but they are not always fatal. With early detection and treatment, many people with cancer can survive and live long, healthy lives.

07/04/2024

It really sucks when you still need to go to work on Sunday, especially when I need to bother my clients on weekend, sorry my friends. 🤣😂

Bioeasy Biotechnology

12/02/2025

05/09/2024

19/08/2024

28/06/2024

17/06/2024

06/05/2024

15/04/2024

07/04/2024

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category